Egr-1: A Target for Scleroderma Therapy PDF Print E-mail
Monday, 26 April 2010 15:10
Two separate research groups funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) have discovered that the molecule EGR-1 (early growth response 1), which regulates gene expression, plays a central role in the development of fibrosis, a condition in which organ-supporting tissue becomes thick, hard, and rigid, hindering normal tissue and organ function. Controlling EGR-1, say the scientists, could be a potential therapy for such disorders as Scleroderma and pulmonary fibrosis. Their findings have been reported in the American Journal of Pathology.

Fibrosis is a disorder of the extracellular matrix, the mesh of proteins like collagen that makes up the body’s connective tissue. It is a factor in scleroderma, among other diseases, and can affect many of the body’s organs, including the lungs, liver, and skin. Its consequences can be devastating, even leading to death. Recent research has shown that cells in fibrotic tissue receive the wrong molecular signals, causing too many extracellular proteins to be made. One possible way to approach the fibrosis problem, scientists say, might be to try to interrupt such signals at critical points in the cellular pathways that they travel.

The two research groups, headed by Carol Feghali-Bostwick, Ph.D., at the University of Pittsburgh School of Medicine and John Varga, M.D ., at Northwestern University’s Feinberg School of Medicine, took separate approaches in discovering the importance of EGR-1. The University of Pittsburgh group induced fibrosis in mouse and human fibroblasts (cells that make up the extracellular matrix) by utilizing a signaling protein called IGFBP-5 (insulin-like growth factor binding protein 5). The Northwestern team administered the antibiotic bleomycin to induce scleroderma in mice. Both research teams found that the experimentally produced fibrosis was associated with abnormally elevated EGR-1 activity.

Furthermore, when they produced fibrosis in cells or in mice lacking EGR-1, the amounts of fibrosis were dramatically reduced. In further support of the findings, the Pittsburgh group found that EGR-1 levels were higher in lung tissues and fibroblasts of people with pulmonary fibrosis compared to controls. EGR-1, concluded the scientists, appears to be essential for the development of fibrosis, making it a potential target for therapy. The two studies also showed that independent signaling pathways, such as those for IGFBP-5 and bleomycin, both converge on EGR-1 to create fibrosis.

Fibrosis is a common disorder and a serious complication of many diseases. It is still considered hard to treat, with no currently approved therapies. Because the understanding of fibrosis is a major unmet medical need, any fresh insights into the disease process might open the door for novel therapies.

Source: 7th Space
 
More articles :

» No Exercise Benefit with Bosentan in Systemic Sclerosis

Treatment with the endothelin receptor antagonist bosentan () failed to improve exercise capacity in patients with systemic sclerosis, a randomized trial found. After one year of treatment, there was a nonsignificant mean change in the six-minute...

» Scleroderma and Lupus Health Study Claims No Environmental Link To Disease

The Massachusetts Department of Public Health (DPH) has released the results of an investigation into the occurrence of and lupus, two rare chronic diseases, in South Boston. The investigation found that the prevalence of scleroderma was indeed...

» Diagnosis, Management and Prevention of Scleroderma Renal Disease

Henry Penn; Christopher P. DentonPosted: 11/14/2008; Curr Opin Rheumatol. 2008;20(6):692-696. © 2008 Lippincott Williams & WilkinsPurpose of Review: Renal complications are important in scleroderma (systemic sclerosis) and include scleroderma...

» The Management and Treatment of Scleroderma is Improving

Management of systemic sclerosis is likely to improve as soon as an ongoing convergence of mechanistic insights, improved understanding of clinical trial design, and interest by industry results in new treatments, according to Dr. Robert F....

» The Mississauga Support Group To Host Annual Fundraiser

The Mississauga Support Group of the Scleroderma Society of Ontario will host its annual fundraising dinner and dance gala on April 2 at the Oasis Convention Centre. Funds raised will go to the Scleroderma Society of Ontario to fund research,...

» Two Problems That People With Scleroderma Face: Malabsorption and Inflammation

According to , many doctors agree that starts with inflammation, and its progress depends on how much inflammation continues to occur in the body. That's one reason some doctors recommend that patients with any sort of inflammatory disease such as...

Comments  

 
+1 #2 Nia 2012-09-16 23:51
i hve sd, very grateful for this research. wouldnt be suprised if there's a vaccine for autoimmune doseases in the not too distant future.
Report to administrator
 
 
+1 #1 Nia 2012-09-16 23:50
Quote:
exciting!
didnt know SD could be induced with an antibiotic...
Report to administrator